ofloxacin has been researched along with Communicable Diseases in 2 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Communicable Diseases: An illness caused by an infectious agent or its toxins that occurs through the direct or indirect transmission of the infectious agent or its products from an infected individual or via an animal, vector or the inanimate environment to a susceptible animal or human host.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases." | 7.69 | Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) |
| "The population pharmacokinetics of levofloxacin (LVFX), the l-enantiomer of ofloxacin, were studied in 522 subjects, including normal subjects and patients with infectious diseases." | 3.69 | Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases. ( Hori, R; Kagimoto, N; Nomura, H; Okumura, K; Tanigawara, Y, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Viale, P | 1 |
| Scudeller, L | 1 |
| Cristini, F | 1 |
| Tanigawara, Y | 1 |
| Nomura, H | 1 |
| Kagimoto, N | 1 |
| Okumura, K | 1 |
| Hori, R | 1 |
2 other studies available for ofloxacin and Communicable Diseases
| Article | Year |
|---|---|
Levofloxacin: a suitable option for the infectious disease consultant.
Topics: Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Cross Infection; Humans; Intensive C | 2004 |
Premarketing population pharmacokinetic study of levofloxacin in normal subjects and patients with infectious diseases.
Topics: Age Factors; Bayes Theorem; Clinical Trials as Topic; Communicable Diseases; Humans; Levofloxacin; M | 1995 |